The outcomes consistently revealed that patients with gliomas with the higher Siglec15 expression had significantly the poorer OS compared to those with a low Siglec15 level in subgroups including age, sex, 1p/19q status, and primary therapy outcome (Figures 2D–G). This evidence concerns the gene SIGLEC15 and central nervous system cancer.